Exosome-Based Therapeutic Development Summit on September 22-24, 2026 in Boston, United States

The exosome therapeutics field is entering a pivotal phase, with companies such as Rion and Capricor Therapeutics advancing into later-stage clinical development beyond Phase 1 and 2 trials. As the pipeline matures, rising regulatory expectations are accelerating the need to evolve exosome platforms into scalable, compliant, and commercially viable therapies. Successfully navigating this transition will require strong industry alignment across clinical strategy, manufacturing, analytics, and regulatory pathways to unlock the next wave of exosome-based therapeutics.

The 8th Exosome-Based Therapeutics Summit returns to Boston, providing a premier platform to connect with leaders in clinical development and manufacturing. Join peers to streamline your CMC strategies, advance your clinical programs, and accelerate your path toward regulatory approval and commercialization.

URLs:

Tickets: https://go.evvnt.com/3670676-2?pid=10008

Brochure: https://go.evvnt.com/3670676-3?pid=10008

Time: 8:00 AM - 4:10 PM

Prices:

Conference + Focus Day - Industry Pricing: USD 4397.00,

Conference + Focus Day - Academic Pricing: USD 3797.00,

Conference + Focus Day - Solution Provider Pricing: USD 5297.00,

Conference Only - Industry Pricing: USD 3099.00,

Conference Only - Academic Pricing: USD 2699.00,

Conference Only - Solution Provider Pricing: USD 3799.00

Speakers: Shelley Hartman, Chief Executive Officer, Aegle Therapeutics, Minghao Sun, Senior Vice President of Product Development, Quality Control and R AND D, Capricor Therapeutics, Jorge Duque, Hemato-Oncologist, Centro Oncologico de Antioquia, Kuldeep Neote, Chief Executive Officer, Diadem Biotherapeutics, Søren Melsing, Chief Executive Officer, Exocure, Dilip Moonka, Medical Director, Liver Transplantation, Henry Ford Health System, Kanika Suri, Independent Scientist, Independent, Mercedes Kweh, Chief Executive Officer and Co-Founder, KweHealth, Silvia Duarte-Sanmiguel, Research and Development Director, Neucore Bio, Wanjun Chen, Senior Investigator, NIH, Tali Kizhner, Director of Manufacturing, NurExone, Lior Shaltiel, Chief Executive Officer, NurExone, Christopher Paradise, Senior Vice President, Research and Development, Rion, Gi-Hoon Nam, Chief Executive Officer, SHIFTBIO, Daniela Paňková, Co-Founder and Chief Executive Officer, Terasom, Spencer Marsh, Chief Scientific Officer, The Tiny Cargo Company, A. M. Rostami, Nicholas Maiale Distinguished professor of Neurology Chairman, Department of Neurology, Thomas Jefferson University, Hai-Yen Vu, Director of Analytics, Versatope Therapeutics, David Haylock, Chief Scientific Officer, VivaZome, Pranav Sharma, Founder and Chief Executive Officer, Xosomix Therapeutics